Bart van Lith

Statistics

Publications

Citations

528

H-Index

Active since

2014

Affiliations

The Ohio State University(Current)

Bart van Lith is an author at The Ohio State University specializing in bruton's tyrosine kinase inhibitors, bruton tyrosine kinase, and btk inhibitors.

Publications per year

2014–2022

Publications

Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile

Tjeerd Barf, Todd Covey, Raquel Izumi et al. · Journal of Pharmacology and Experimental Therapeutics · 2017 · 370 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma

Bonnie K. Harrington, Heather L. Gardner, Raquel Izumi et al. · PLoS ONE · 2016 · 58 citations · Full text

Medicine, Oncology, Pharmacology +14

Abstract 2596: ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients

Todd Covey, Tjeerd Barf, Michael Gulrajani et al. · Cancer Research · 2015 · 45 citations

Medicine, Medicinal Chemistry, Pharmacology +13

Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors

Terry Podoll, Paul G. Pearson, Allard Kaptein et al. · Journal of Pharmacology and Experimental Therapeutics · 2022 · 22 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity

Bonnie K. Harrington, Michael Gulrajani, Todd Covey et al. · Blood · 2015 · 21 citations

Life Sciences, Medicinal Chemistry, Pharmacology +14

1–5 of 6